Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients
Date
1996Author
Fountzilas, GeorgePolichronis, A.
Katsohis, C.
Gennatas, Constantinos
Toussis, D.
Skarlos, Dimosthenis V.
Kosmidis, Paraskevas A.
Vassilaros, S.
Semoglou, C.
Giannakakis, T.
Fahantidis, E.
Klouvas, G. D.
Tsavaris, N.
Konstantaras, C.
Makrantonakis, P.
Kolotas, C.
Zamboglou, N.
Tsiliakos, S.
Hainoglou, D.
Mylonakis, N.

Source
Oncology (Switzerland)Volume
53Issue
2Pages
137-146Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/ m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p = 0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment. © 1996 S. Karger AG, Basel.